Healthcare Resource Utilisation and Costs in Patients with Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Analysis of German Insurance Claims Data
These real-world data highlight the substantial economic burden associated with EGPA, characterised by increased HCRU, costs and productivity losses, underscoring the need for effective management strategies.
Authors
- Chris Edmonds
- Keltie McDonald (ORCID: https://orcid.org/0000-0002-0204-9049)
- Anat Shavit
- Antje Mevius (ORCID: https://orcid.org/0000-0002-9556-6693)
- Bernhard Hellmich (ORCID: https://orcid.org/0000-0002-8014-1801)
- Jennie Rowell
- Josefine Persson (ORCID: https://orcid.org/0000-0003-4308-3523)
- Danuta Kielar (ORCID: https://orcid.org/0009-0003-1814-1100)
- Stephanie Chen (ORCID: https://orcid.org/0000-0002-9004-3682)
- Paul Dolin
Institutions
- AstraZeneca (United Kingdom) (GB)
- Wismar University of Applied Sciences (DE)
- AstraZeneca (Netherlands) (NL)
- AstraZeneca (Switzerland) (CH)
- AstraZeneca (Japan) (JP)
- AstraZeneca (Italy) (IT)
- AstraZeneca (Sweden) (SE)
- AstraZeneca (United States) (US)
- Cytel (United States) (US)
Publication Details
- Journal
- Rheumatology and Therapy
- Published
- 2025-10-17
- DOI
- https://doi.org/10.1007/s40744-025-00795-1
- Primary Topic
- Vasculitis and related conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca